<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Investigational methods in the diagnosis of acute kidney allograft rejection</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Investigational methods in the diagnosis of acute kidney allograft rejection</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Investigational methods in the diagnosis of acute kidney allograft rejection</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Dany Anglicheau, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Andrew Malone, MB, BCh, FASN, FRCPI</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">W James Chon, MD, FACP, FASN, FAST</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Daniel C Brennan, MD, FACP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Christophe Legendre, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Albert Q Lam, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 03, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H625052259"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>For decades, routine monitoring of allograft function after kidney transplantation has relied upon the use of nonspecific markers, such as serum creatinine, glomerular filtration rate (GFR), and proteinuria. The definitive diagnosis of kidney allograft dysfunction still requires an invasive allograft biopsy, which remains the gold standard for the assessment of graft status. Given their low sensitivity, existing markers fail to detect subclinical changes, and pathologic processes are often recognized at a relatively advanced stage. "Protocol" or screening biopsies have been proposed in kidney transplant recipients to identify early pathologic changes that may be evident before graft dysfunction. However, a number of limitations reduce the utility of screening biopsies in clinical practice: Biopsies are invasive, and complications may occur; sampling errors may jeopardize their diagnostic utility; and the procedures are costly and labor intensive. (See  <a class="medical medical_review" href="/z/d/html/14039.html" rel="external">"Overview of care of the adult kidney transplant recipient", section on 'Monitoring kidney allograft function'</a>.)</p><p>Innovative biomarkers have been developed to circumvent the shortcomings of existing methods for monitoring allograft function. Although several such markers have been found to provide good diagnostic and/or prognostic utility, few, if any, are used in clinical practice, and there is insufficient evidence that their use will lead to meaningful improvements in graft outcome [<a href="#rid1">1</a>]. Additional barriers that limit the introduction of novel biomarkers into clinical practice include regulatory issues, generalizability, cost, ease of interpretation, and identification of patient populations who may benefit from more than standard-of-care surveillance.</p><p>This topic will review investigational methods in the diagnosis of acute rejection of the kidney allograft. The clinical features, diagnosis, treatment, and prognosis of kidney allograft rejection, and the evaluation and diagnosis of kidney allograft dysfunction, are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7352.html" rel="external">"Kidney transplantation in adults: Clinical features and diagnosis of acute kidney allograft rejection"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7358.html" rel="external">"Kidney transplantation in adults: Treatment of acute T cell-mediated (cellular) rejection"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7326.html" rel="external">"Kidney transplantation in adults: Prevention and treatment of antibody-mediated rejection"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7301.html" rel="external">"Kidney transplantation in adults: Evaluation and diagnosis of acute kidney allograft dysfunction"</a>.)</p><p></p><p class="headingAnchor" id="H1302659884"><span class="h1">LIMITATIONS OF CURRENTLY USED BIOMARKERS</span></p><p class="headingAnchor" id="H136228172"><span class="h2">Kidney allograft biopsy</span><span class="headingEndMark"> — </span>Although imperfect, the kidney allograft biopsy remains the gold standard to identify the mechanisms of graft injury in kidney transplant recipients [<a href="#rid2">2,3</a>]. Assessment of the predictive performance of a biomarker (ie, sensitivity, specificity, and positive and negative predictive values) requires knowledge of the actual diagnosis. Because allograft biopsies are considered the gold standard, it is impossible to determine their sensitivity and specificity, despite known limitations of biopsy data. Specifically, the problem of sampling error likely results in biopsies that do not include tissue that is adversely affected by pathologic processes, thereby increasing the proportion of false-negative tests (ie, the absence of a histologic lesion is not proof of the absence of this lesion). However, no other diagnostic method can provide information about the true state of the allograft, and, therefore, the actual diagnostic performance of the allograft biopsy remains unknown. In addition, pathologists frequently vary in their interpretation of biopsy findings. (See  <a class="medical medical_review" href="/z/d/html/14039.html" rel="external">"Overview of care of the adult kidney transplant recipient", section on 'Kidney biopsy'</a>.)</p><p class="headingAnchor" id="H2803572088"><span class="h2">Serum creatinine</span><span class="headingEndMark"> — </span>Serum creatinine concentration is one of the primary markers used to monitor kidney allograft function in clinical practice. Early graft function, as determined by measurement of serum creatinine at one year posttransplant, has been shown to predict long-term graft survival [<a href="#rid4">4</a>]. However, at an individual level, a serum creatinine value is neither sensitive nor specific for graft injury [<a href="#rid5">5</a>]. Subclinical rejection develops in the absence of overt graft dysfunction. In addition, an increase in serum creatinine after transplantation may reflect a variety of underlying processes including acute tubular injury, immunosuppressive drug toxicity, obstructive nephropathy, and infection-associated nephropathy. (See  <a class="medical medical_review" href="/z/d/html/14039.html" rel="external">"Overview of care of the adult kidney transplant recipient", section on 'Serum creatinine and GFR'</a> and  <a class="medical medical_review" href="/z/d/html/7301.html" rel="external">"Kidney transplantation in adults: Evaluation and diagnosis of acute kidney allograft dysfunction", section on 'Causes of acute allograft dysfunction'</a>.)</p><p class="headingAnchor" id="H3625025425"><span class="h2">Proteinuria</span><span class="headingEndMark"> — </span>Proteinuria is routinely measured with serum creatinine to monitor graft function after kidney transplantation [<a href="#rid6">6,7</a>]. Several observational studies have shown that increased urine protein excretion posttransplant is an important and independent predictor of graft failure [<a href="#rid8">8-13</a>]. However, albuminuria and proteinuria are nonspecific markers of graft injury, and an association between proteinuria and specific pathologic processes in the kidney allograft has not been well described [<a href="#rid8">8,9,14</a>]. One study of 1518 kidney transplant recipients evaluated the diagnostic and prognostic performance of measuring proteinuria after transplantation, at the time of graft dysfunction (with clinically indicated biopsies), and during routine clinical follow-up (with protocol biopsies) [<a href="#rid13">13</a>]. After three months posttransplant, proteinuria &gt;1 g/24 hours at the time of a clinically indicated biopsy had a high specificity (85 to 91 percent) but low sensitivity (21 to 48 percent) for the combination of transplant glomerulopathy, microcirculation inflammation, and/or de novo/recurrent glomerular disease. Thus, biomarkers that are more sensitive for detecting potentially treatable graft injuries are needed. (See  <a class="medical medical_review" href="/z/d/html/14039.html" rel="external">"Overview of care of the adult kidney transplant recipient", section on 'Proteinuria'</a>.)</p><p class="headingAnchor" id="H1200350870"><span class="h2">DSA monitoring</span><span class="headingEndMark"> — </span>High levels of preformed donor-specific antibodies (DSAs) at the time of transplantation are generally considered a contraindication for successful transplantation. Low levels of DSAs, which are not a contraindication to transplant, may subsequently lead to a wide spectrum of antibody-mediated graft injuries and, therefore, require individual risk assessment. While advances in screening methods have increased the sensitivity for detecting very low levels of DSAs, the specificity and positive predictive value (PPV) of DSA for the risk of developing antibody-mediated rejection (ABMR) have decreased. As an example, in one study of 402 deceased-donor kidney transplant recipients, the sensitivity, specificity, and PPV of a remote positive complement-dependent cytotoxicity crossmatch for detecting subsequent ABMR were 41, 97, and 54 percent [<a href="#rid15">15</a>]. By comparison, with the single-antigen (Luminex) bead assay, the sensitivity, specificity, and PPV of a preformed DSA on the peak serum were 91, 85, and 35 percent. (See  <a class="medical medical_review" href="/z/d/html/7352.html" rel="external">"Kidney transplantation in adults: Clinical features and diagnosis of acute kidney allograft rejection"</a> and  <a class="medical medical_review" href="/z/d/html/7326.html" rel="external">"Kidney transplantation in adults: Prevention and treatment of antibody-mediated rejection", section on 'Predictors of outcome'</a>.)</p><p>Additional evidence has suggested that the development of DSAs after transplantation (ie, de novo DSAs) is associated with decreased graft survival [<a href="#rid16">16,17</a>]. However, despite the widespread use of posttransplant monitoring for DSAs, the utility of this strategy to noninvasively diagnose ABMR or predict long-term graft outcomes has not been clearly evaluated. In one study of 281 indication biopsies (ie, biopsies performed in the setting of allograft dysfunction) in 244 kidney transplant recipients, the presence of DSA (both preexisting and de novo) at the time of allograft biopsy was associated with the diagnosis of ABMR (odds ratio [OR] 3.6 and 10.4 for mean fluorescence intensity [MFI] of 1000 to 3000 and &gt;3000, respectively) [<a href="#rid5">5</a>]. However, many patients with DSAs did not have ABMR, suggesting that DSA should be considered as a risk factor for rather than diagnostic of ABMR. Another study reported an association between de novo DSAs and the histologic findings of peritubular capillaritis and C4d deposition on allograft biopsy, but the percentage of biopsies meeting the criteria for ABMR was not provided [<a href="#rid16">16</a>].</p><p class="headingAnchor" id="H2061370073"><span class="h1">NONINVASIVE BIOMARKERS</span><span class="headingEndMark"> — </span>The limitations of existing markers of kidney allograft dysfunction highlight the need for innovative, robust, and, ideally, noninvasive methods to predict and diagnose acute and chronic graft injury. The development of "omics" methods (eg, genomics, transcriptomics, proteomics, metabolomics) in the field of transplantation has paved the way for the development of several candidate biomarkers [<a href="#rid18">18-24</a>]. The following discussion will highlight some of these approaches to noninvasive or minimally invasive monitoring of the kidney transplant.</p><p class="headingAnchor" id="H2080638379"><span class="h2">Functional cell-based immune monitoring</span><span class="headingEndMark"> — </span>Alloreactive memory T cells are central mediators of kidney allograft rejection, and monitoring the activity of these cells may help to identify transplant recipients who are at risk for acute rejection (see  <a class="medical medical_review" href="/z/d/html/7346.html" rel="external">"Transplantation immunobiology", section on 'Effector mechanisms associated with allograft rejection'</a>). The interferon (IFN)-gamma enzyme-linked immunospot assay (ELISPOT), which measures IFN-gamma secretion by recipient T cells in response to donor antigens, is one test that has been used to assess antidonor T cell alloreactivity in vitro [<a href="#rid25">25</a>]. Several studies have found that pretransplant T cell alloreactivity, as determined by the IFN-gamma ELISPOT, may be associated with an increased risk of posttransplant acute rejection and lower posttransplant graft function [<a href="#rid25">25-30</a>]. However, in one multicenter observational study of 176 kidney transplant recipients, a correlation between pretransplant ELISPOT reactivity and acute rejection or posttransplant graft function was only observed in patients who did not receive induction therapy with <a class="drug drug_general" data-topicid="10026" href="/z/d/drug information/10026.html" rel="external">rabbit antithymocyte globulin</a> (rATG)-Thymoglobulin [<a href="#rid31">31</a>]. One study found that the persistence of donor-specific T cell alloreactivity at 6 months after transplantation, under conditions of potent immunosuppression, was associated with subclinical T cell-mediated rejection (TCMR) and worse allograft function at 12 months posttransplant [<a href="#rid32">32</a>].</p><p>Although assays such as the IFN-gamma ELISPOT may be helpful in monitoring T cell alloreactivity and memory B cells, wider application may be limited by their laborious, time-consuming, and impractical use in clinical practice. </p><p class="headingAnchor" id="H3353510235"><span class="h2">Molecular blood biomarkers</span><span class="headingEndMark"> — </span>Several studies have identified potential biomarkers in peripheral blood that may identify patients with acute kidney allograft rejection [<a href="#rid33">33-42</a>], including subclinical acute rejection [<a href="#rid43">43,44</a>]. The following discussion will focus on important advances in the field of peripheral blood messenger ribonucleic acid (mRNA) and donor-derived cell-free DNA (dd-cfDNA) analysis and the diagnosis and prediction of acute rejection.</p><p class="headingAnchor" id="H3469527830"><span class="h3">Kidney Solid Organ Response Test (kSORT)</span><span class="headingEndMark"> — </span>The Kidney Solid Organ Response Test (kSORT) is a microarray-based assay that was developed to detect patients at high risk for acute rejection [<a href="#rid40">40</a>]. The test, performed on a peripheral blood sample, employs quantitative polymerase chain reaction (PCR) to measure the relative mRNA expression levels of 17 genes known to be associated with acute rejection or leukocyte trafficking. A correlation-based algorithm was then used to generate risk scores and classify patients into high, low, or indeterminate risk of acute rejection. The utility of the kSORT assay was initially evaluated in a large multicenter study of 436 adult and pediatric kidney transplant recipients (Assessment of Acute Rejection in Renal Transplantation [AART]) with paired peripheral blood samples and kidney allograft biopsies (performed for allograft dysfunction or as part of a clinical protocol) using mainly a case-control study design of selected patients [<a href="#rid40">40</a>]. The kSORT assay was able to predict patients at high risk of acute rejection (either TCMR or antibody-mediated rejection [ABMR]) with a sensitivity and specificity of 92 and 93 percent, respectively. In addition, kSORT was able to identify 12 of 16 biopsies with subclinical rejection and could predict clinical rejection in more than 60 percent of samples collected within three months before the diagnosis of biopsy-confirmed acute rejection. However, the test was unable to distinguish between acute TCMR and ABMR.</p><p>A subsequent study evaluated the use of kSORT and the IFN-gamma ELISPOT assays (see <a class="local">'Functional cell-based immune monitoring'</a> above) in predicting subclinical acute rejection [<a href="#rid41">41</a>]. In a cohort of 75 kidney transplant recipients, combined use of both the kSORT and ELISPOT assays improved the predictive probability for subclinical acute rejection and the ability to distinguish between subclinical TCMR and ABMR. However, a subsequent large, multicenter study of 1134 patients using blood samples obtained under real-world clinical conditions was unable to validate the utility of the kSORT assay for the detection of acute rejection in the first year after transplantation [<a href="#rid45">45</a>].</p><p class="headingAnchor" id="H3918187303"><span class="h3">TruGraf v1 assay</span><span class="headingEndMark"> — </span>The TruGraf assay is a DNA microarray-based gene expression blood test that was developed as an alternative to surveillance biopsies to rule out subclinical rejection in patients with stable graft function [<a href="#rid46">46</a>]. All aspects of discovery and external validation of the TruGraf test were performed on blood samples paired with protocol biopsies from prevalent cohorts. How the test performs in patients with graft dysfunction has not been assessed and remains to be studied. One study found that combining the TruGraf assay with dd-cfDNA, another noninvasive biomarker used for the diagnosis of acute rejection, improved the detection of subclinical rejection [<a href="#rid47">47</a>]. (See  <a class="medical medical_review" href="/z/d/html/7352.html" rel="external">"Kidney transplantation in adults: Clinical features and diagnosis of acute kidney allograft rejection"</a>.)</p><p class="headingAnchor" id="H1802730120"><span class="h3">Other peripheral blood assays</span><span class="headingEndMark"> — </span>Other assays have been developed to distinguish patients with and without acute rejection based upon the analysis of peripheral blood samples. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>In one multicenter study, global gene expression profiling was performed on peripheral blood samples from 148 kidney transplant recipients with normal histology and stable graft function (46 patients), biopsy-proven acute rejection (63 patients), or acute allograft dysfunction without rejection (39 patients) [<a href="#rid42">42</a>]. Analysis of these data identified 200 probe sets that distinguished patients with acute rejection from those without rejection with a sensitivity of 82 to 100 percent and specificity of 76 to 95 percent. However, the study was limited by the lack of prospective validation and absence of patients with ABMR. A prospective trial evaluating the diagnostic and prognostic utility of this assay in 300 kidney transplant recipients is in progress.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>One study found that a 17-gene signature in peripheral blood could identify patients with subclinical and borderline TCMR at three months posttransplant [<a href="#rid44">44</a>]. Such patients had a higher risk of subsequent clinical acute rejection at 12 and 24 months, faster decline in graft function, and decreased graft survival compared with those without subclinical or borderline TCMR at three months posttransplant.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A multicenter study from the European BIOMARGIN consortium developed and validated an eight-gene expression assay for the diagnosis of ABMR [<a href="#rid48">48</a>]. This assay was able to differentiate between cases with and without ABMR with good diagnostic accuracy (area under the receiver operative characteristic curve [ROC AUC] 79.9 percent, 95% CI 72.6-87.2), both at the time of stable graft function and at the time of graft dysfunction. Adding a clinical model for the diagnosis of ABMR to the eight-gene assay further improved diagnostic accuracy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Quantification of microRNAs (miRNAs) in peripheral blood may represent a noninvasive biomarker for evaluation of allograft status. In one study, combined measurement of five miRNAs (miR-15B, miR-16, miR-103A, miR-106A, and miR-107) in peripheral blood samples enhanced the sensitivity and specificity for the diagnosis of severe T cell-mediated vascular rejection [<a href="#rid37">37</a>].</p><p></p><p class="headingAnchor" id="H31008019"><span class="h2">Urine biomarkers</span><span class="headingEndMark"> — </span>Several urinary biomarkers, including mRNAs, miRNAs, and proteins and peptides, have been proposed as noninvasive biomarkers for the diagnosis and prognosis of acute rejection.</p><p class="headingAnchor" id="H2052715489"><span class="h3">Urine messenger RNAs</span><span class="headingEndMark"> — </span>Acute TCMR is characterized by interstitial inflammation and tubulitis with graft-infiltrating cells entering into the tubular space. This has led some investigators to hypothesize that the kidney allograft may function as an "in vivo flow cytometer" that sorts cells involved in rejection into the urine and that profiling of the urinary cell mRNA could serve as a noninvasive method to diagnose acute TCMR [<a href="#rid19">19,49</a>]. Single-center studies of urinary cell mRNA profiling identified several potential mRNAs (eg, perforin, granzyme B, IFN-inducible protein-10 [IP-10], CD3), the levels of which predicted the diagnosis of acute TCMR [<a href="#rid50">50-53</a>]. The most promising of these markers were prospectively evaluated in a large, multicenter study (Clinical Trials in Organ Transplantation 04 [CTOT4]) of 485 kidney transplant recipients [<a href="#rid54">54</a>]. A three-gene signature of CD3-epsilon mRNA, IP-10 mRNA, and 18S ribosomal RNA (rRNA) was able to distinguish between kidney biopsy specimens showing acute TCMR and those without rejection with a sensitivity of 71 to 79 percent and specificity of 72 to 78 percent. In addition, the molecular signature could distinguish acute TCMR from borderline rejection, acute ABMR, or chronic allograft nephropathy with a sensitivity and specificity of 79 and 71 percent, respectively. Evaluation of the three-gene signature in repeated urine samples over time suggested that this test could also predict the development of acute TCMR weeks before the onset of graft dysfunction. Global transcriptional analysis of urinary cell samples with RNA sequencing has also identified enriched gene signatures and pathways associated with TCMR and ABMR [<a href="#rid55">55</a>].</p><p>While these results appear promising, the potential for extensive degradation of mRNAs in urine is one important limitation of this assay. In the CTOT4 study cited above, for example, only 83 percent of urine samples passed quality control standards [<a href="#rid54">54</a>]. However, despite this limitation, a multicenter evaluation of a standardized protocol for urinary cell mRNA profiling demonstrated a reasonably good concordance between laboratories, confirming the potential of this technique in real-life clinical settings [<a href="#rid56">56</a>].</p><p class="headingAnchor" id="H1830938275"><span class="h3">Urine microRNAs</span><span class="headingEndMark"> — </span>Quantification of miRNA in urine samples has also emerged as an alternative method to assess allograft status [<a href="#rid57">57</a>]. The following studies illustrate the range of findings:</p><p class="bulletIndent1"><span class="glyph">●</span>In an initial study that profiled urinary miRNAs of stable transplant patients and those with acute TCMR, miR-10a, miR-10b, and miR-210 were strongly deregulated in the urine of patients with acute TCMR [<a href="#rid58">58</a>]. Low miR-210 levels were also associated with a greater decline in glomerular filtration rate (GFR) at one year posttransplant.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>One study evaluated miRNA expression profiles in allograft biopsy tissue and paired urine samples of transplant recipients with chronic allograft dysfunction and interstitial fibrosis/tubular atrophy (IF/TA) and those with normal allografts [<a href="#rid59">59</a>]. Fifty-six miRNAs were identified as differentially expressed in biopsy samples with IF/TA; five of these (miR-142-3p, miR-204, miR-107, miR-211, and miR-32) were confirmed using an independent set of samples. Differential expression of miR-142-3p, miR-204, and miR-211 in the urine of patients with IF/TA was also observed. Findings of a second study suggested that the combination of miRNA profiling of biopsy and urine samples could be used to monitor graft function and predict progression to chronic allograft dysfunction [<a href="#rid60">60</a>].</p><p></p><p>These preliminary findings will need to be validated in independent and unselected populations to assess the diagnostic and/or prognostic accuracy as well as the clinical utility of urine miRNAs. In addition, as the aforementioned studies quantified miRNAs in whole urine, urine cell pellets, or cell-free urine supernatant, the ideal medium to be used for urine miRNA profiling is uncertain.</p><p class="headingAnchor" id="H1596512771"><span class="h3">Urine proteins</span><span class="headingEndMark"> — </span>A number of urinary immune-related proteins have been identified as biomarkers of acute rejection of the kidney allograft [<a href="#rid61">61</a>]. As examples, elevated urinary levels of chemokine (C-X-C motif) ligands 9 and 10 (CXCL9 and CXCL10) have been associated with acute TCMR [<a href="#rid61">61-68</a>]. In a multicenter observational study of 280 adult and pediatric kidney transplant recipients (Clinical Trial in Organ Transplant [CTOT1]) that evaluated multiple urinary proteins and mRNAs as biomarkers of acute rejection, elevated urinary CXCL9 levels had a PPV and NPV of 68 and 92 percent, respectively, for diagnosing Banff ≥1A TCMR [<a href="#rid62">62</a>]. Urinary levels of CXCL10 are also elevated in patients with ABMR [<a href="#rid5">5</a>]. In a study of 244 kidney transplant patients, elevated urinary CXCL10 levels had a PPV and NPV of 55 and 86 percent for the diagnosis of ABMR. However, increased urinary CXCL9 and CXCL10 levels have also been detected in patients with BK polyomavirus (BKPyV) infection [<a href="#rid66">66</a>], suggesting that these chemokines may represent markers of allograft inflammation rather than specific diagnostic markers of acute rejection. One study in kidney transplant recipients found that urinary CXCL10 levels increased with BKPyV viremia but not with isolated viruria [<a href="#rid69">69</a>]. </p><p>Some studies have suggested that measuring urinary chemokines may have prognostic value in kidney transplant recipients. One study, for example, found that urinary concentration of chemokine (C-C motif) ligand 2 (CCL2, also known as monocyte chemoattractant protein 1 [MPC1]) at six months posttransplant was a predictor of severe IF/TA and graft dysfunction at two years posttransplant [<a href="#rid70">70,71</a>]. In the CTOT1 study cited above, patients with stable allografts and low urinary CXCL9 levels at 6 months posttransplant were least likely to subsequently develop TCMR or a reduction in estimated GFR (eGFR) between 6 and 24 months [<a href="#rid62">62</a>]. Similarly, in another study, low urinary CXCL10 levels at one and three months posttransplant were associated with improved rejection-free allograft survival at one year posttransplant [<a href="#rid72">72</a>]. Urinary CXCL10 at three months independently predicted the subsequent development of clinical acute rejection with a PPV and NPV of 13 and 97 percent, respectively. Although the PPV was low, the high NPV suggested that urinary CXCL10 levels could serve to identify patients at low risk of rejection who might be optimal candidates for immunosuppressive drug weaning.</p><p class="headingAnchor" id="H267431526"><span class="h3">Urine proteomics/peptidomics</span><span class="headingEndMark"> — </span>High-throughput methods have been used to identify proteomic and peptidomic signatures of acute rejection in urine and blood samples. Several studies have suggested that proteomic or peptidomic signatures can be used to noninvasively diagnose acute rejection with high sensitivity and specificity [<a href="#rid73">73</a>]. Proteins and peptides differentially expressed in patients with acute rejection have been identified, including fragments of collagens, beta-2-microglobulin, alpha-1-antichymotrypsin, and uromodulin. In addition, the high-throughput approach has enabled pathway-enrichment analysis that has uncovered key pathogenic processes, such as major histocompatibility complex (MHC) antigen presentation; IFN-gamma and integrin signaling; complement activation; platelet function; and keratin sulfate, glycosaminoglycan, and collagen metabolism.</p><p>While these findings support the applicability of proteomic approaches in the diagnosis of acute rejection, additional points need to be addressed. As an example, fewer studies have performed proteomic profiling of other histopathologic entities such as subclinical rejection [<a href="#rid74">74-76</a>], ABMR [<a href="#rid77">77-81</a>], mixed rejection [<a href="#rid82">82</a>], and chronic rejection phenotypes [<a href="#rid78">78,79,83</a>], which have only more recently been specifically defined in the Banff classification system. In addition, the lack of large-scale studies prevents the assessment of confounding factors, such as urinary tract infection, cytomegalovirus infection, or BKV nephropathy, or of superimposed histologic lesions such as acute tubular injury [<a href="#rid84">84</a>] that may associate with distinct proteomic signatures. Thus, longitudinal evaluation of these new assays should be performed in unselected, consecutively recruited patients [<a href="#rid73">73</a>]. Another aspect that has not been addressed is the potential use of proteomic approaches as prognostic biomarkers (ie, to anticipate rejection or graft outcome) or as predictive biomarkers (ie, to assess response to antirejection treatment). Finally, implementing proteomic markers into widespread clinical application will require standardization of the preanalytical procedures for sample preparation and development of simplified test systems.</p><p class="headingAnchor" id="H3507312152"><span class="h2">Imaging methods</span><span class="headingEndMark"> — </span>In addition to the biomarkers discussed above, medical imaging methods have also been developed as noninvasive approaches to diagnosing graft dysfunction and assessing graft status. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>In one study of 31 kidney transplant recipients with suspected acute rejection, 18-fluoro-2-deoxyglucose (FDG) positron emission tomography coupled with computed tomography (PET/CT) was able to distinguish nonrejection from acute rejection [<a href="#rid85">85</a>], suggesting that this test might be used to identify patients for whom an allograft biopsy could be avoided.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Assessment of high-energy phosphates metabolism using 31-phosphorus magnetic resonance spectroscopy (MRS) has been used to evaluate kidney allograft status. One study of kidney transplant recipients with type 1 diabetes found that kidney-pancreas transplantation, compared with kidney-alone transplantation, was associated with a higher beta-adenosine triphosphate (ATP)/inorganic phosphorus ratio (a marker of graft energy status), suggesting that restoration of beta cell function positively affects kidney graft metabolism [<a href="#rid86">86</a>].</p><p></p><p class="headingAnchor" id="H1020585076"><span class="h1">INVASIVE BIOMARKERS</span><span class="headingEndMark"> — </span>Although there are several advantages to the use of noninvasive biomarkers, invasive diagnostic tests are frequently necessary to confirm the diagnosis when noninvasive testing reveals a high probability of active disease [<a href="#rid24">24</a>]. Invasive biomarkers may also be required to detect subclinical disease when sensitive noninvasive biomarkers are not available.</p><p class="headingAnchor" id="H2571143113"><span class="h2">The molecular microscope</span><span class="headingEndMark"> — </span>The "molecular microscope diagnostic system" (MMDx) is a microarray-based system that analyzes messenger RNA (mRNA) expression patterns in transplant biopsy tissue to predict the diagnosis of acute T cell-mediated rejection (TCMR) or antibody-mediated rejection (ABMR) [<a href="#rid87">87</a>]. This technology was developed with the hypothesis that the diagnosis of specific disease states can be established on the basis of mRNA levels in the biopsy sample [<a href="#rid87">87,88</a>].</p><p>The general procedure for the MMDx is as follows [<a href="#rid87">87,89</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>A kidney allograft biopsy sample (obtained with an 18 gauge or larger biopsy needle) is preserved in a tissue storage reagent that stabilizes RNA, then shipped by courier to a central processing laboratory that performs MMDx.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>RNA is extracted from the biopsy sample, and a microarray analysis is performed to measure mRNA levels.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Predefined computer algorithms (known as classifiers) are used to generate a report (typically within 29 hours) that compares the results of the microarray analysis with a reference set of biopsy samples with established diagnoses. The report provides molecular scores that reflect the probability that the biopsy sample has histologic features of TCMR [<a href="#rid90">90</a>], ABMR [<a href="#rid91">91</a>], rejection of any type [<a href="#rid92">92</a>], acute kidney injury (AKI) [<a href="#rid93">93</a>], or interstitial fibrosis/tubular atrophy (IF/TA) [<a href="#rid94">94</a>].</p><p></p><p>The development of this assay was based upon the findings of several studies in kidney transplant patients that characterized and validated the molecular phenotypes ("molecular landscapes") for TCMR, ABMR, AKI, and IF/TA [<a href="#rid87">87,90-100</a>]. The following studies illustrate the range of findings:</p><p class="bulletIndent1"><span class="glyph">●</span>In one study, microarray results from 403 kidney transplant biopsies (35 with a diagnosis of TCMR) were used to derive a classifier that assigned TCMR scores to all biopsies; scores were then compared with the histologic diagnosis of the biopsies [<a href="#rid90">90</a>]. Transcripts that distinguished biopsies with TCMR from other transplant biopsies were primarily associated with effector T cell and macrophage infiltration and activation. Molecular scores correlated with histologic lesions of TCMR (tubulitis and interstitial infiltration) with an accuracy of 89 percent. The positive predictive value (PPV) and negative predictive value (NPV) of a high TCMR molecular score (≥0.1) for predicting the histologic diagnosis of TCMR were 62 and 92 percent, respectively.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a parallel study from the same group, microarray results from the same 403 kidney transplant biopsies (56 with a histologic/donor-specific antibody [DSA] diagnosis of ABMR) were used to derive a classifier that assigned ABMR scores to all biopsies [<a href="#rid91">91</a>]. Most of the transcripts that distinguished biopsies with ABMR from other transplant biopsies were expressed in natural killer (NK) cells or endothelial cells or were interferon (IFN)-gamma inducible. A positive ABMR molecular score (≥0.2) had a PPV and NPV of 64 and 91 percent, respectively, for predicting the histologic/DSA diagnosis of ABMR. In addition, ABMR molecular scores were strongly associated with DSA positivity and were an independent predictor of graft failure.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The performance of the TCMR and ABMR molecular scoring systems was prospectively evaluated in a multicenter study (Integrated Diagnostic System in the International Collaborative Microarray [INTERCOM]) of 300 kidney transplant biopsies from 264 patients [<a href="#rid95">95,96</a>]. Histologic diagnoses of TCMR or ABMR (including C4d-positive ABMR, C4d-negative ABMR, and mixed ABMR and TCMR rejection) were present in 11 and 15 percent of biopsies, respectively. A TCMR molecular score of ≥0.1 predicted the histologic diagnosis of TCMR (including borderline rejection) with a PPV and NPV of 49 and 94 percent, respectively. Similarly, an ABMR molecular score of ≥0.2 predicted the diagnosis of ABMR or mixed rejection with PPV and NPV of 50 and 94 percent, respectively. There was no significant difference in the ABMR score between biopsies with C4d-positive ABMR and those with C4d-negative ABMR. A positive ABMR score in late biopsies (performed more than one year posttransplant) was significantly associated with death-censored graft loss at three years (hazard ratio [HR] 2.93, 95% CI 1.97-4.36); no association between the TCMR score and death-censored graft loss was observed.</p><p></p><p>Collectively, the results of these studies demonstrate that molecular phenotyping of kidney transplant biopsies is capable of discriminating between rejection and nonrejection at least as well as, if not better than, histologic evaluation and DSA alone. Discrepancies between molecular and histologic diagnoses, as evidenced by the relatively low PPVs in the studies discussed above, reflect a combination of issues including histologic errors or ambiguity, MMDx errors, and sampling differences (ie, different biopsy cores assessed by histology and MMDx) [<a href="#rid87">87</a>]. Microarray analysis of kidney allograft biopsy tissue has also been used to predict the risk of fibrosis and allograft loss [<a href="#rid101">101</a>].</p><p>Alternative methods have been developed and applied for transcriptomic analysis of the kidney allograft, including RNA sequencing [<a href="#rid102">102</a>] and the NanoString technology [<a href="#rid103">103</a>]. </p><p class="headingAnchor" id="H4158314186"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Limitations of existing biomarkers </strong>– Routine monitoring of allograft function after kidney transplantation has relied upon the use of nonspecific markers, such as serum creatinine, glomerular filtration rate (GFR), proteinuria, and donor-specific antibodies (DSAs). The definitive diagnosis of kidney allograft dysfunction still requires an invasive allograft biopsy, which remains the gold standard for the assessment of graft status. Given their low sensitivity, existing markers fail to detect subclinical changes, and pathologic processes are often recognized at a relatively advanced stage. (See <a class="local">'Limitations of currently used biomarkers'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Investigational biomarkers </strong>– Innovative strategies have been developed to circumvent the limitations of existing biomarkers.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Several noninvasive monitoring tools have been proposed that use easily accessible biologic fluids such as urine and blood, allowing frequent and sequential assessments of a recipient's immune status. These include functional cell-based assays and the evaluation of molecular expression, at the messenger RNA (mRNA) or protein level, on a wide spectrum of platforms. (See <a class="local">'Noninvasive biomarkers'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Molecular technologies, including the molecular microscope diagnostic system (MMDx), have been developed as a refinement of the histologic evaluation of the allograft biopsy. (See <a class="local">'The molecular microscope'</a> above.)</p><p></p><p class="bulletIndent1">The translation and validation of exploratory findings and their implementation into standard clinical practice remain challenging. Dedicated, prospective, interventional trials are required to demonstrate that the use of these biomarkers improves patient or transplant outcomes. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Barriers to use in clinical practice </strong>– Significant barriers exist that limit the introduction of novel biomarkers into clinical practice. These include regulatory issues, generalizability, cost, ease of interpretation, and also identification of patient populations who may benefit from more than standard-of-care surveillance.</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Matas AJ, Gaston RS. Moving Beyond Minimization Trials in Kidney Transplantation. J Am Soc Nephrol 2015; 26:2898.</a></li><li><a class="nounderline abstract_t">Henderson LK, Nankivell BJ, Chapman JR. Surveillance protocol kidney transplant biopsies: their evolving role in clinical practice. Am J Transplant 2011; 11:1570.</a></li><li><a class="nounderline abstract_t">Naesens M. Zero-Time Renal Transplant Biopsies: A Comprehensive Review. Transplantation 2016; 100:1425.</a></li><li><a class="nounderline abstract_t">Hariharan S, McBride MA, Cherikh WS, et al. Post-transplant renal function in the first year predicts long-term kidney transplant survival. Kidney Int 2002; 62:311.</a></li><li><a class="nounderline abstract_t">Rabant M, Amrouche L, Lebreton X, et al. Urinary C-X-C Motif Chemokine 10 Independently Improves the Noninvasive Diagnosis of Antibody-Mediated Kidney Allograft Rejection. J Am Soc Nephrol 2015; 26:2840.</a></li><li><a class="nounderline abstract_t">Nankivell BJ, Kuypers DR. Diagnosis and prevention of chronic kidney allograft loss. Lancet 2011; 378:1428.</a></li><li><a class="nounderline abstract_t">Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009; 9 Suppl 3:S1.</a></li><li><a class="nounderline abstract_t">Legendre C, Anglicheau D. Transplantation: Proteinuria in kidney transplantation: an ongoing story. Nat Rev Nephrol 2013; 9:251.</a></li><li><a class="nounderline abstract_t">Tsampalieros A, Knoll GA. Evaluation and Management of Proteinuria After Kidney Transplantation. Transplantation 2015; 99:2049.</a></li><li><a class="nounderline abstract_t">Amer H, Fidler ME, Myslak M, et al. Proteinuria after kidney transplantation, relationship to allograft histology and survival. Am J Transplant 2007; 7:2748.</a></li><li><a class="nounderline abstract_t">Cherukuri A, Welberry-Smith MP, Tattersall JE, et al. The clinical significance of early proteinuria after renal transplantation. Transplantation 2010; 89:200.</a></li><li><a class="nounderline abstract_t">Halimi JM, Buchler M, Al-Najjar A, et al. Urinary albumin excretion and the risk of graft loss and death in proteinuric and non-proteinuric renal transplant recipients. Am J Transplant 2007; 7:618.</a></li><li><a class="nounderline abstract_t">Naesens M, Lerut E, Emonds MP, et al. Proteinuria as a Noninvasive Marker for Renal Allograft Histology and Failure: An Observational Cohort Study. J Am Soc Nephrol 2016; 27:281.</a></li><li><a class="nounderline abstract_t">Amer H, Lieske JC, Rule AD, et al. Urine high and low molecular weight proteins one-year post-kidney transplant: relationship to histology and graft survival. Am J Transplant 2013; 13:676.</a></li><li><a class="nounderline abstract_t">Lefaucheur C, Loupy A, Hill GS, et al. Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol 2010; 21:1398.</a></li><li><a class="nounderline abstract_t">Wiebe C, Gibson IW, Blydt-Hansen TD, et al. Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant 2012; 12:1157.</a></li><li><a class="nounderline abstract_t">Wiebe C, Gibson IW, Blydt-Hansen TD, et al. Rates and determinants of progression to graft failure in kidney allograft recipients with de novo donor-specific antibody. Am J Transplant 2015; 15:2921.</a></li><li><a class="nounderline abstract_t">Lo DJ, Kaplan B, Kirk AD. Biomarkers for kidney transplant rejection. Nat Rev Nephrol 2014; 10:215.</a></li><li><a class="nounderline abstract_t">Anglicheau D, Suthanthiran M. Noninvasive prediction of organ graft rejection and outcome using gene expression patterns. Transplantation 2008; 86:192.</a></li><li><a class="nounderline abstract_t">Anglicheau D, Naesens M, Essig M, et al. Establishing Biomarkers in Transplant Medicine: A Critical Review of Current Approaches. Transplantation 2016; 100:2024.</a></li><li><a class="nounderline abstract_t">Naesens M, Sarwal MM. Molecular diagnostics in transplantation. Nat Rev Nephrol 2010; 6:614.</a></li><li><a class="nounderline abstract_t">Perkins D, Verma M, Park KJ. Advances of genomic science and systems biology in renal transplantation: a review. Semin Immunopathol 2011; 33:211.</a></li><li><a class="nounderline abstract_t">Traitanon O, Poggio ED, Fairchild RL. Molecular monitoring of alloimmune-mediated injury in kidney transplant patients. Curr Opin Nephrol Hypertens 2014; 23:625.</a></li><li><a class="nounderline abstract_t">Naesens M, Anglicheau D. Precision Transplant Medicine: Biomarkers to the Rescue. J Am Soc Nephrol 2018; 29:24.</a></li><li><a class="nounderline abstract_t">Hricik DE, Rodriguez V, Riley J, et al. Enzyme linked immunosorbent spot (ELISPOT) assay for interferon-gamma independently predicts renal function in kidney transplant recipients. Am J Transplant 2003; 3:878.</a></li><li><a class="nounderline abstract_t">Augustine JJ, Siu DS, Clemente MJ, et al. Pre-transplant IFN-gamma ELISPOTs are associated with post-transplant renal function in African American renal transplant recipients. Am J Transplant 2005; 5:1971.</a></li><li><a class="nounderline abstract_t">Kim SH, Oh EJ, Kim MJ, et al. Pretransplant donor-specific interferon-gamma ELISPOT assay predicts acute rejection episodes in renal transplant recipients. Transplant Proc 2007; 39:3057.</a></li><li><a class="nounderline abstract_t">Koscielska-Kasprzak K, Drulis-Fajdasz D, Kaminska D, et al. Pretransplantation cellular alloreactivity is predictive of acute graft rejection and 1-year graft function in kidney transplant recipients. Transplant Proc 2009; 41:3006.</a></li><li><a class="nounderline abstract_t">Näther BJ, Nickel P, Bold G, et al. Modified ELISPOT technique--highly significant inverse correlation of post-Tx donor-reactive IFNgamma-producing cell frequencies with 6 and 12 months graft function in kidney transplant recipients. Transpl Immunol 2006; 16:232.</a></li><li><a class="nounderline abstract_t">Nickel P, Presber F, Bold G, et al. Enzyme-linked immunosorbent spot assay for donor-reactive interferon-gamma-producing cells identifies T-cell presensitization and correlates with graft function at 6 and 12 months in renal-transplant recipients. Transplantation 2004; 78:1640.</a></li><li><a class="nounderline abstract_t">Hricik DE, Augustine J, Nickerson P, et al. Interferon Gamma ELISPOT Testing as a Risk-Stratifying Biomarker for Kidney Transplant Injury: Results From the CTOT-01 Multicenter Study. Am J Transplant 2015; 15:3166.</a></li><li><a class="nounderline abstract_t">Bestard O, Cruzado JM, Lucia M, et al. Prospective assessment of antidonor cellular alloreactivity is a tool for guidance of immunosuppression in kidney transplantation. Kidney Int 2013; 84:1226.</a></li><li><a class="nounderline abstract_t">Aquino-Dias EC, Joelsons G, da Silva DM, et al. Non-invasive diagnosis of acute rejection in kidney transplants with delayed graft function. Kidney Int 2008; 73:877.</a></li><li><a class="nounderline abstract_t">Günther OP, Balshaw RF, Scherer A, et al. Functional genomic analysis of peripheral blood during early acute renal allograft rejection. Transplantation 2009; 88:942.</a></li><li><a class="nounderline abstract_t">Kurian SM, Heilman R, Mondala TS, et al. Biomarkers for early and late stage chronic allograft nephropathy by proteogenomic profiling of peripheral blood. PLoS One 2009; 4:e6212.</a></li><li><a class="nounderline abstract_t">Li L, Ying L, Naesens M, et al. Interference of globin genes with biomarker discovery for allograft rejection in peripheral blood samples. Physiol Genomics 2008; 32:190.</a></li><li><a class="nounderline abstract_t">Matz M, Fabritius K, Lorkowski C, et al. Identification of T Cell-Mediated Vascular Rejection After Kidney Transplantation by the Combined Measurement of 5 Specific MicroRNAs in Blood. Transplantation 2016; 100:898.</a></li><li><a class="nounderline abstract_t">Rascio F, Pontrelli P, Accetturo M, et al. A type I interferon signature characterizes chronic antibody-mediated rejection in kidney transplantation. J Pathol 2015; 237:72.</a></li><li><a class="nounderline abstract_t">Simon T, Opelz G, Wiesel M, et al. Serial peripheral blood perforin and granzyme B gene expression measurements for prediction of acute rejection in kidney graft recipients. Am J Transplant 2003; 3:1121.</a></li><li><a class="nounderline abstract_t">Roedder S, Sigdel T, Salomonis N, et al. The kSORT assay to detect renal transplant patients at high risk for acute rejection: results of the multicenter AART study. PLoS Med 2014; 11:e1001759.</a></li><li><a class="nounderline abstract_t">Crespo E, Roedder S, Sigdel T, et al. Molecular and Functional Noninvasive Immune Monitoring in the ESCAPE Study for Prediction of Subclinical Renal Allograft Rejection. Transplantation 2017; 101:1400.</a></li><li><a class="nounderline abstract_t">Kurian SM, Williams AN, Gelbart T, et al. Molecular classifiers for acute kidney transplant rejection in peripheral blood by whole genome gene expression profiling. Am J Transplant 2014; 14:1164.</a></li><li><a class="nounderline abstract_t">Friedewald JJ, Kurian SM, Heilman RL, et al. Development and clinical validity of a novel blood-based molecular biomarker for subclinical acute rejection following kidney transplant. Am J Transplant 2019; 19:98.</a></li><li><a class="nounderline abstract_t">Zhang W, Yi Z, Keung KL, et al. A Peripheral Blood Gene Expression Signature to Diagnose Subclinical Acute Rejection. J Am Soc Nephrol 2019; 30:1481.</a></li><li><a class="nounderline abstract_t">Van Loon E, Giral M, Anglicheau D, et al. Diagnostic performance of kSORT, a blood-based mRNA assay for noninvasive detection of rejection after kidney transplantation: A retrospective multicenter cohort study. Am J Transplant 2021; 21:740.</a></li><li><a class="nounderline abstract_t">Marsh CL, Kurian SM, Rice JC, et al. Application of TruGraf v1: A Novel Molecular Biomarker for Managing Kidney Transplant Recipients With Stable Renal Function. Transplant Proc 2019; 51:722.</a></li><li><a class="nounderline abstract_t">Park S, Guo K, Heilman RL, et al. Combining Blood Gene Expression and Cellfree DNA to Diagnose Subclinical Rejection in Kidney Transplant Recipients. Clin J Am Soc Nephrol 2021; 16:1539.</a></li><li><a class="nounderline abstract_t">Van Loon E, Gazut S, Yazdani S, et al. Development and validation of a peripheral blood mRNA assay for the assessment of antibody-mediated kidney allograft rejection: A multicentre, prospective study. EBioMedicine 2019; 46:463.</a></li><li><a class="nounderline abstract_t">Lee JR, Muthukumar T, Dadhania D, et al. Urinary cell mRNA profiles predictive of human kidney allograft status. Immunol Rev 2014; 258:218.</a></li><li><a class="nounderline abstract_t">Li B, Hartono C, Ding R, et al. Noninvasive diagnosis of renal-allograft rejection by measurement of messenger RNA for perforin and granzyme B in urine. N Engl J Med 2001; 344:947.</a></li><li><a class="nounderline abstract_t">Muthukumar T, Ding R, Dadhania D, et al. Serine proteinase inhibitor-9, an endogenous blocker of granzyme B/perforin lytic pathway, is hyperexpressed during acute rejection of renal allografts. Transplantation 2003; 75:1565.</a></li><li><a class="nounderline abstract_t">Ding R, Li B, Muthukumar T, et al. CD103 mRNA levels in urinary cells predict acute rejection of renal allografts. Transplantation 2003; 75:1307.</a></li><li><a class="nounderline abstract_t">Hancock WW, Lu B, Gao W, et al. Requirement of the chemokine receptor CXCR3 for acute allograft rejection. J Exp Med 2000; 192:1515.</a></li><li><a class="nounderline abstract_t">Suthanthiran M, Schwartz JE, Ding R, et al. Urinary-cell mRNA profile and acute cellular rejection in kidney allografts. N Engl J Med 2013; 369:20.</a></li><li><a class="nounderline abstract_t">Verma A, Muthukumar T, Yang H, et al. Urinary cell transcriptomics and acute rejection in human kidney allografts. JCI Insight 2020; 5.</a></li><li><a class="nounderline abstract_t">Keslar KS, Lin M, Zmijewska AA, et al. Multicenter evaluation of a standardized protocol for noninvasive gene expression profiling. Am J Transplant 2013; 13:1891.</a></li><li><a class="nounderline abstract_t">Amrouche L, Rabant M, Anglicheau D. MicroRNAs as biomarkers of graft outcome. Transplant Rev (Orlando) 2014; 28:111.</a></li><li><a class="nounderline abstract_t">Lorenzen JM, Volkmann I, Fiedler J, et al. Urinary miR-210 as a mediator of acute T-cell mediated rejection in renal allograft recipients. Am J Transplant 2011; 11:2221.</a></li><li><a class="nounderline abstract_t">Scian MJ, Maluf DG, David KG, et al. MicroRNA profiles in allograft tissues and paired urines associate with chronic allograft dysfunction with IF/TA. Am J Transplant 2011; 11:2110.</a></li><li><a class="nounderline abstract_t">Maluf DG, Dumur CI, Suh JL, et al. The urine microRNA profile may help monitor post-transplant renal graft function. Kidney Int 2014; 85:439.</a></li><li><a class="nounderline abstract_t">Hirt-Minkowski P, De Serres SA, Ho J. Developing renal allograft surveillance strategies - urinary biomarkers of cellular rejection. Can J Kidney Health Dis 2015; 2:28.</a></li><li><a class="nounderline abstract_t">Hricik DE, Nickerson P, Formica RN, et al. Multicenter validation of urinary CXCL9 as a risk-stratifying biomarker for kidney transplant injury. Am J Transplant 2013; 13:2634.</a></li><li><a class="nounderline abstract_t">Schaub S, Nickerson P, Rush D, et al. Urinary CXCL9 and CXCL10 levels correlate with the extent of subclinical tubulitis. Am J Transplant 2009; 9:1347.</a></li><li><a class="nounderline abstract_t">Hu H, Kwun J, Aizenstein BD, Knechtle SJ. Noninvasive detection of acute and chronic injuries in human renal transplant by elevation of multiple cytokines/chemokines in urine. Transplantation 2009; 87:1814.</a></li><li><a class="nounderline abstract_t">Hu H, Aizenstein BD, Puchalski A, et al. Elevation of CXCR3-binding chemokines in urine indicates acute renal-allograft dysfunction. Am J Transplant 2004; 4:432.</a></li><li><a class="nounderline abstract_t">Jackson JA, Kim EJ, Begley B, et al. Urinary chemokines CXCL9 and CXCL10 are noninvasive markers of renal allograft rejection and BK viral infection. Am J Transplant 2011; 11:2228.</a></li><li><a class="nounderline abstract_t">Ho J, Rush DN, Karpinski M, et al. Validation of urinary CXCL10 as a marker of borderline, subclinical, and clinical tubulitis. Transplantation 2011; 92:878.</a></li><li><a class="nounderline abstract_t">Hricik DE, Formica RN, Nickerson P, et al. Adverse Outcomes of Tacrolimus Withdrawal in Immune-Quiescent Kidney Transplant Recipients. J Am Soc Nephrol 2015; 26:3114.</a></li><li><a class="nounderline abstract_t">Tinel C, Vermorel A, Picciotto D, et al. Deciphering the Prognostic and Predictive Value of Urinary CXCL10 in Kidney Recipients With BK Virus Reactivation. Front Immunol 2020; 11:604353.</a></li><li><a class="nounderline abstract_t">Ho J, Rush DN, Gibson IW, et al. Early urinary CCL2 is associated with the later development of interstitial fibrosis and tubular atrophy in renal allografts. Transplantation 2010; 90:394.</a></li><li><a class="nounderline abstract_t">Ho J, Wiebe C, Gibson IW, et al. Elevated urinary CCL2: Cr at 6 months is associated with renal allograft interstitial fibrosis and inflammation at 24 months. Transplantation 2014; 98:39.</a></li><li><a class="nounderline abstract_t">Rabant M, Amrouche L, Morin L, et al. Early Low Urinary CXCL9 and CXCL10 Might Predict Immunological Quiescence in Clinically and Histologically Stable Kidney Recipients. Am J Transplant 2016; 16:1868.</a></li><li><a class="nounderline abstract_t">Gwinner W, Metzger J, Husi H, Marx D. Proteomics for rejection diagnosis in renal transplant patients: Where are we now? World J Transplant 2016; 6:28.</a></li><li><a class="nounderline abstract_t">Mao Y, Yu J, Chen J, et al. Diagnosis of renal allograft subclinical rejection by urine protein fingerprint analysis. Transpl Immunol 2008; 18:255.</a></li><li><a class="nounderline abstract_t">Metzger J, Chatzikyrkou C, Broecker V, et al. Diagnosis of subclinical and clinical acute T-cell-mediated rejection in renal transplant patients by urinary proteome analysis. Proteomics Clin Appl 2011; 5:322.</a></li><li><a class="nounderline abstract_t">Wittke S, Haubitz M, Walden M, et al. Detection of acute tubulointerstitial rejection by proteomic analysis of urinary samples in renal transplant recipients. Am J Transplant 2005; 5:2479.</a></li><li><a class="nounderline abstract_t">Akkina SK, Zhang Y, Nelsestuen GL, et al. Temporal stability of the urinary proteome after kidney transplant: more sensitive than protein composition? J Proteome Res 2009; 8:94.</a></li><li><a class="nounderline abstract_t">Quintana LF, Campistol JM, Alcolea MP, et al. Application of label-free quantitative peptidomics for the identification of urinary biomarkers of kidney chronic allograft dysfunction. Mol Cell Proteomics 2009; 8:1658.</a></li><li><a class="nounderline abstract_t">Quintana LF, Solé-Gonzalez A, Kalko SG, et al. Urine proteomics to detect biomarkers for chronic allograft dysfunction. J Am Soc Nephrol 2009; 20:428.</a></li><li><a class="nounderline abstract_t">Sigdel TK, Salomonis N, Nicora CD, et al. The identification of novel potential injury mechanisms and candidate biomarkers in renal allograft rejection by quantitative proteomics. Mol Cell Proteomics 2014; 13:621.</a></li><li><a class="nounderline abstract_t">Yang H, Mao Y, Yu J, et al. Diagnosis of c4d+ renal allograft acute humoral rejection by urine protein fingerprint analysis. J Int Med Res 2010; 38:176.</a></li><li><a class="nounderline abstract_t">Pisitkun T, Gandolfo MT, Das S, et al. Application of systems biology principles to protein biomarker discovery: urinary exosomal proteome in renal transplantation. Proteomics Clin Appl 2012; 6:268.</a></li><li><a class="nounderline abstract_t">Jahnukainen T, Malehorn D, Sun M, et al. Proteomic analysis of urine in kidney transplant patients with BK virus nephropathy. J Am Soc Nephrol 2006; 17:3248.</a></li><li><a class="nounderline abstract_t">Gwinner W, Hinzmann K, Erdbruegger U, et al. Acute tubular injury in protocol biopsies of renal grafts: prevalence, associated factors and effect on long-term function. Am J Transplant 2008; 8:1684.</a></li><li><a class="nounderline abstract_t">Lovinfosse P, Weekers L, Bonvoisin C, et al. Fluorodeoxyglucose F(18) Positron Emission Tomography Coupled With Computed Tomography in Suspected Acute Renal Allograft Rejection. Am J Transplant 2016; 16:310.</a></li><li><a class="nounderline abstract_t">Fiorina P, Perseghin G, De Cobelli F, et al. Altered kidney graft high-energy phosphate metabolism in kidney-transplanted end-stage renal disease type 1 diabetic patients: a cross-sectional analysis of the effect of kidney alone and kidney-pancreas transplantation. Diabetes Care 2007; 30:597.</a></li><li><a class="nounderline abstract_t">Halloran PF, Famulski KS, Reeve J. Molecular assessment of disease states in kidney transplant biopsy samples. Nat Rev Nephrol 2016; 12:534.</a></li><li><a class="nounderline abstract_t">Strom TB, Suthanthiran M. Transcriptional profiling to assess the clinical status of kidney transplants. Nat Clin Pract Nephrol 2006; 2:116.</a></li><li><a class="nounderline abstract_t">Halloran PF, Reeve J, Akalin E, et al. Real Time Central Assessment of Kidney Transplant Indication Biopsies by Microarrays: The INTERCOMEX Study. Am J Transplant 2017; 17:2851.</a></li><li><a class="nounderline abstract_t">Reeve J, Sellarés J, Mengel M, et al. Molecular diagnosis of T cell-mediated rejection in human kidney transplant biopsies. Am J Transplant 2013; 13:645.</a></li><li><a class="nounderline abstract_t">Sellarés J, Reeve J, Loupy A, et al. Molecular diagnosis of antibody-mediated rejection in human kidney transplants. Am J Transplant 2013; 13:971.</a></li><li><a class="nounderline abstract_t">Reeve J, Einecke G, Mengel M, et al. Diagnosing rejection in renal transplants: a comparison of molecular- and histopathology-based approaches. Am J Transplant 2009; 9:1802.</a></li><li><a class="nounderline abstract_t">Famulski KS, de Freitas DG, Kreepala C, et al. Molecular phenotypes of acute kidney injury in kidney transplants. J Am Soc Nephrol 2012; 23:948.</a></li><li><a class="nounderline abstract_t">Venner JM, Famulski KS, Reeve J, et al. Relationships among injury, fibrosis, and time in human kidney transplants. JCI Insight 2016; 1:e85323.</a></li><li><a class="nounderline abstract_t">Halloran PF, Pereira AB, Chang J, et al. Potential impact of microarray diagnosis of T cell-mediated rejection in kidney transplants: The INTERCOM study. Am J Transplant 2013; 13:2352.</a></li><li><a class="nounderline abstract_t">Halloran PF, Pereira AB, Chang J, et al. Microarray diagnosis of antibody-mediated rejection in kidney transplant biopsies: an international prospective study (INTERCOM). Am J Transplant 2013; 13:2865.</a></li><li><a class="nounderline abstract_t">Mengel M, Reeve J, Bunnag S, et al. Molecular correlates of scarring in kidney transplants: the emergence of mast cell transcripts. Am J Transplant 2009; 9:169.</a></li><li><a class="nounderline abstract_t">Mueller TF, Einecke G, Reeve J, et al. Microarray analysis of rejection in human kidney transplants using pathogenesis-based transcript sets. Am J Transplant 2007; 7:2712.</a></li><li><a class="nounderline abstract_t">Venner JM, Hidalgo LG, Famulski KS, et al. The molecular landscape of antibody-mediated kidney transplant rejection: evidence for NK involvement through CD16a Fc receptors. Am J Transplant 2015; 15:1336.</a></li><li><a class="nounderline abstract_t">Venner JM, Famulski KS, Badr D, et al. Molecular landscape of T cell-mediated rejection in human kidney transplants: prominence of CTLA4 and PD ligands. Am J Transplant 2014; 14:2565.</a></li><li><a class="nounderline abstract_t">O'Connell PJ, Zhang W, Menon MC, et al. Biopsy transcriptome expression profiling to identify kidney transplants at risk of chronic injury: a multicentre, prospective study. Lancet 2016; 388:983.</a></li><li><a class="nounderline abstract_t">Mueller FB, Yang H, Lubetzky M, et al. Landscape of innate immune system transcriptome and acute T cell-mediated rejection of human kidney allografts. JCI Insight 2019; 4.</a></li><li><a class="nounderline abstract_t">Mengel M, Loupy A, Haas M, et al. Banff 2019 Meeting Report: Molecular diagnostics in solid organ transplantation-Consensus for the Banff Human Organ Transplant (B-HOT) gene panel and open source multicenter validation. Am J Transplant 2020; 20:2305.</a></li></ol></div><div id="topicVersionRevision">Topic 7325 Version 18.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25925686" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Moving Beyond Minimization Trials in Kidney Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21797971" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Surveillance protocol kidney transplant biopsies: their evolving role in clinical practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26599490" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Zero-Time Renal Transplant Biopsies: A Comprehensive Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12081593" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Post-transplant renal function in the first year predicts long-term kidney transplant survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25948873" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Urinary C-X-C Motif Chemokine 10 Independently Improves the Noninvasive Diagnosis of Antibody-Mediated Kidney Allograft Rejection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22000139" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Diagnosis and prevention of chronic kidney allograft loss.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19845597" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : KDIGO clinical practice guideline for the care of kidney transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23545590" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Transplantation: Proteinuria in kidney transplantation: an ongoing story.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26335919" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Evaluation and Management of Proteinuria After Kidney Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17941956" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Proteinuria after kidney transplantation, relationship to allograft histology and survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20098283" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : The clinical significance of early proteinuria after renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17217438" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Urinary albumin excretion and the risk of graft loss and death in proteinuric and non-proteinuric renal transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26152270" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Proteinuria as a Noninvasive Marker for Renal Allograft Histology and Failure: An Observational Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23414180" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Urine high and low molecular weight proteins one-year post-kidney transplant: relationship to histology and graft survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20634297" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22429309" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26096305" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Rates and determinants of progression to graft failure in kidney allograft recipients with de novo donor-specific antibody.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24445740" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Biomarkers for kidney transplant rejection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18645476" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Noninvasive prediction of organ graft rejection and outcome using gene expression patterns.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27479159" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Establishing Biomarkers in Transplant Medicine: A Critical Review of Current Approaches.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20736923" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Molecular diagnostics in transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21318414" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Advances of genomic science and systems biology in renal transplantation: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25202838" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Molecular monitoring of alloimmune-mediated injury in kidney transplant patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28993504" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Precision Transplant Medicine: Biomarkers to the Rescue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12814480" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Enzyme linked immunosorbent spot (ELISPOT) assay for interferon-gamma independently predicts renal function in kidney transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15996247" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Pre-transplant IFN-gamma ELISPOTs are associated with post-transplant renal function in African American renal transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18089321" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Pretransplant donor-specific interferon-gamma ELISPOT assay predicts acute rejection episodes in renal transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19857662" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Pretransplantation cellular alloreactivity is predictive of acute graft rejection and 1-year graft function in kidney transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17138059" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Modified ELISPOT technique--highly significant inverse correlation of post-Tx donor-reactive IFNgamma-producing cell frequencies with 6 and 12 months graft function in kidney transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15591953" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Enzyme-linked immunosorbent spot assay for donor-reactive interferon-gamma-producing cells identifies T-cell presensitization and correlates with graft function at 6 and 12 months in renal-transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26226830" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Interferon Gamma ELISPOT Testing as a Risk-Stratifying Biomarker for Kidney Transplant Injury: Results From the CTOT-01 Multicenter Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23783240" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Prospective assessment of antidonor cellular alloreactivity is a tool for guidance of immunosuppression in kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18216781" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Non-invasive diagnosis of acute rejection in kidney transplants with delayed graft function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19935467" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Functional genomic analysis of peripheral blood during early acute renal allograft rejection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19593431" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Biomarkers for early and late stage chronic allograft nephropathy by proteogenomic profiling of peripheral blood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17971501" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Interference of globin genes with biomarker discovery for allograft rejection in peripheral blood samples.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26444957" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Identification of T Cell-Mediated Vascular Rejection After Kidney Transplantation by the Combined Measurement of 5 Specific MicroRNAs in Blood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25925804" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : A type I interferon signature characterizes chronic antibody-mediated rejection in kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12919092" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Serial peripheral blood perforin and granzyme B gene expression measurements for prediction of acute rejection in kidney graft recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25386950" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : The kSORT assay to detect renal transplant patients at high risk for acute rejection: results of the multicenter AART study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27362314" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Molecular and Functional Noninvasive Immune Monitoring in the ESCAPE Study for Prediction of Subclinical Renal Allograft Rejection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24725967" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Molecular classifiers for acute kidney transplant rejection in peripheral blood by whole genome gene expression profiling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29985559" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Development and clinical validity of a novel blood-based molecular biomarker for subclinical acute rejection following kidney transplant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31278196" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : A Peripheral Blood Gene Expression Signature to Diagnose Subclinical Acute Rejection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32627407" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Diagnostic performance of kSORT, a blood-based mRNA assay for noninvasive detection of rejection after kidney transplantation: A retrospective multicenter cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30979456" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Application of TruGraf v1: A Novel Molecular Biomarker for Managing Kidney Transplant Recipients With Stable Renal Function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34620649" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Combining Blood Gene Expression and Cellfree DNA to Diagnose Subclinical Rejection in Kidney Transplant Recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31378695" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Development and validation of a peripheral blood mRNA assay for the assessment of antibody-mediated kidney allograft rejection: A multicentre, prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24517436" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Urinary cell mRNA profiles predictive of human kidney allograft status.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11274620" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Noninvasive diagnosis of renal-allograft rejection by measurement of messenger RNA for perforin and granzyme B in urine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12792516" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Serine proteinase inhibitor-9, an endogenous blocker of granzyme B/perforin lytic pathway, is hyperexpressed during acute rejection of renal allografts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12717221" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : CD103 mRNA levels in urinary cells predict acute rejection of renal allografts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11085753" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Requirement of the chemokine receptor CXCR3 for acute allograft rejection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23822777" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Urinary-cell mRNA profile and acute cellular rejection in kidney allografts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32102984" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Urinary cell transcriptomics and acute rejection in human kidney allografts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23802725" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Multicenter evaluation of a standardized protocol for noninvasive gene expression profiling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24797471" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : MicroRNAs as biomarkers of graft outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21812927" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Urinary miR-210 as a mediator of acute T-cell mediated rejection in renal allograft recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21794090" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : MicroRNA profiles in allograft tissues and paired urines associate with chronic allograft dysfunction with IF/TA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24025639" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : The urine microRNA profile may help monitor post-transplant renal graft function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26285614" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Developing renal allograft surveillance strategies - urinary biomarkers of cellular rejection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23968332" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Multicenter validation of urinary CXCL9 as a risk-stratifying biomarker for kidney transplant injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19459809" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Urinary CXCL9 and CXCL10 levels correlate with the extent of subclinical tubulitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19543058" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Noninvasive detection of acute and chronic injuries in human renal transplant by elevation of multiple cytokines/chemokines in urine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14961998" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Elevation of CXCR3-binding chemokines in urine indicates acute renal-allograft dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21812928" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Urinary chemokines CXCL9 and CXCL10 are noninvasive markers of renal allograft rejection and BK viral infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21876477" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Validation of urinary CXCL10 as a marker of borderline, subclinical, and clinical tubulitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25925687" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Adverse Outcomes of Tacrolimus Withdrawal in Immune-Quiescent Kidney Transplant Recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33362789" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Deciphering the Prognostic and Predictive Value of Urinary CXCL10 in Kidney Recipients With BK Virus Reactivation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20625355" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Early urinary CCL2 is associated with the later development of interstitial fibrosis and tubular atrophy in renal allografts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24646773" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Elevated urinary CCL2: Cr at 6 months is associated with renal allograft interstitial fibrosis and inflammation at 24 months.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26694099" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Early Low Urinary CXCL9 and CXCL10 Might Predict Immunological Quiescence in Clinically and Histologically Stable Kidney Recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27011903" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Proteomics for rejection diagnosis in renal transplant patients: Where are we now?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18047934" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Diagnosis of renal allograft subclinical rejection by urine protein fingerprint analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21538920" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Diagnosis of subclinical and clinical acute T-cell-mediated rejection in renal transplant patients by urinary proteome analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16162198" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Detection of acute tubulointerstitial rejection by proteomic analysis of urinary samples in renal transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19012427" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Temporal stability of the urinary proteome after kidney transplant: more sensitive than protein composition?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19357086" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Application of label-free quantitative peptidomics for the identification of urinary biomarkers of kidney chronic allograft dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19056874" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Urine proteomics to detect biomarkers for chronic allograft dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24335474" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : The identification of novel potential injury mechanisms and candidate biomarkers in renal allograft rejection by quantitative proteomics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20233527" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Diagnosis of c4d+ renal allograft acute humoral rejection by urine protein fingerprint analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22641613" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Application of systems biology principles to protein biomarker discovery: urinary exosomal proteome in renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17035609" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Proteomic analysis of urine in kidney transplant patients with BK virus nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18557733" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Acute tubular injury in protocol biopsies of renal grafts: prevalence, associated factors and effect on long-term function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26302136" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Fluorodeoxyglucose F(18) Positron Emission Tomography Coupled With Computed Tomography in Suspected Acute Renal Allograft Rejection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17327327" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Altered kidney graft high-energy phosphate metabolism in kidney-transplanted end-stage renal disease type 1 diabetic patients: a cross-sectional analysis of the effect of kidney alone and kidney-pancreas transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27345248" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Molecular assessment of disease states in kidney transplant biopsy samples.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16932404" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Transcriptional profiling to assess the clinical status of kidney transplants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28449409" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Real Time Central Assessment of Kidney Transplant Indication Biopsies by Microarrays: The INTERCOMEX Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23356949" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Molecular diagnosis of T cell-mediated rejection in human kidney transplant biopsies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23414212" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Molecular diagnosis of antibody-mediated rejection in human kidney transplants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19519809" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Diagnosing rejection in renal transplants: a comparison of molecular- and histopathology-based approaches.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22343120" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Molecular phenotypes of acute kidney injury in kidney transplants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27699214" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Relationships among injury, fibrosis, and time in human kidney transplants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23915426" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Potential impact of microarray diagnosis of T cell-mediated rejection in kidney transplants: The INTERCOM study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24119109" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Microarray diagnosis of antibody-mediated rejection in kidney transplant biopsies: an international prospective study (INTERCOM).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18976290" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Molecular correlates of scarring in kidney transplants: the emergence of mast cell transcripts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17941957" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Microarray analysis of rejection in human kidney transplants using pathogenesis-based transcript sets.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25787894" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : The molecular landscape of antibody-mediated kidney transplant rejection: evidence for NK involvement through CD16a Fc receptors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25219326" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Molecular landscape of T cell-mediated rejection in human kidney transplants: prominence of CTLA4 and PD ligands.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27452608" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Biopsy transcriptome expression profiling to identify kidney transplants at risk of chronic injury: a multicentre, prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31292297" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Landscape of innate immune system transcriptome and acute T cell-mediated rejection of human kidney allografts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32428337" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Banff 2019 Meeting Report: Molecular diagnostics in solid organ transplantation-Consensus for the Banff Human Organ Transplant (B-HOT) gene panel and open source multicenter validation.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
